🧬 Interested in pharma, biotech and medical device news? Visit PharmaDeviceNews.com →

Dr. Reddy’s launches Sputnik V Covid vaccine in India at Rs 995 per dose

Dr. Reddy’s Laboratories has launched the Sputnik V Covid vaccine in India with the first dose of the Russian vaccine administered today in Hyderabad.

The soft launch of the Russian coronavirus vaccine follows the landing of the first batch of its imported doses in India earlier this month and the subsequent regulatory clearance from the Central Drugs Laboratory in Kasauli.

Dr. Reddy’s Laboratories said that further consignments of imported doses are anticipated to land in the country over the upcoming months.

The company said that the supply of the human adenoviral vector platform-based Sputnik V vaccine will start from Indian manufacturing partners.

Dr. Reddy's Laboratories launches Sputnik V Covid vaccine in India at INR 995 per dose
Dr. Reddy’s Laboratories launches Sputnik V Covid vaccine in India at INR 995 per dose. Photo courtesy of The Russian Direct Investment Fund.

Currently, the imported doses of the Russian coronavirus vaccine are priced at INR 948 + 5% GST per dose. Dr. Reddy’s Laboratories said that there is scope for reducing the Covid vaccine price when local supply kicks off.

The Indian pharma giant said that it is closely working with its six manufacturing partners in the country to meet regulatory requirements for ensuring seamless and timely supply.

Furthermore, Dr. Reddy’s Laboratories will closely work with stakeholders in the Indian government and private sector for ensuring that the Sputnik V Covid vaccine has the widest possible reach as part of the country’s inoculation effort.

G V Prasad – Co-Chairman and Managing Director of Dr. Reddy’s Laboratories said: “With the rising cases in India, vaccination is our most effective tool in our battle against COVID-19. Contributing to the vaccination drive in India is our biggest priority right now to help Indians be healthy and safe.”


Discover more from Business-News-Today.com

Subscribe to get the latest posts sent to your email.

Total
0
Shares
Related Posts
Infographic showing Molecular Partners’ plan to cut up to 55 jobs, or about 44% of its workforce, while refocusing on targeted radiotherapy and lead Radio-DARPin candidate MP0712 ahead of expected efficacy data in 2027.
Read More

Molecular Partners (NASDAQ: MOLN) plans 44% workforce cut as MP0712 becomes central to strategy

Molecular Partners plans to eliminate up to 55 positions, or roughly 44% of its workforce, as it reshapes itself around targeted radiotherapy and its lead Radio-DARPin candidate MP0712. The strategic concentration could extend resources around a promising platform, but the company is making that organisational commitment before efficacy data from MP0712 are expected in 2027.